FDA.reportPublic FDA data

vamorolone 40 MG/ML Oral Suspension [Agamree]

RxCUI
2669810
RxNorm name
vamorolone 40 MG/ML Oral Suspension [Agamree]
Display name
vamorolone 40 MG/ML Oral Suspension [Agamree]
Full name
vamorolone 40 MG/ML Oral Suspension [Agamree]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:29

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AGAMREEVAMOROLONECatalyst Pharmaceuticals, Inc.fb376f09-cf9c-42b5-b4dd-02d5bcd732112026-01-22Warnings, Adverse reactionsExact identifier
rxcui: 2669810

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
fb376f09-cf9c-42b5-b4dd-02d5bcd73211AGAMREE 40 MG/mL Oral Suspension [PSN] · vamorolone 40 MG/ML Oral Suspension [Agamree] [SBD] · Agamree 40 MG/ML Oral Suspension [SY]310These highlights do not include all the information needed to use AGAMREE ® safely and effectively. See full prescribing information for AGAMREE. AGAMREE (vamorolone) oral suspension Initial U.S. Approval: 202320260122